Morgan Keegan Reports Good Quarter For Boston Scientific

According to Morgan Keegan, Boston Scientific BSX had a good quarter. Morgan Keegan said that the quarter was good coming in at the high end or beating consensus, but the story still is that the company is meeting its long-term strategic plan's milestones. “Third quarter estimates lowered because of CRM weakness as well has higher SG&A and tax expenses; however yearly EPS guidance raised to $0.64-$0.70 ($0.41-$0.47 inc. amort.) from $0.58-$0.68 ex. amortization.” Boston Scientific closed yesterday at $7.28.